Bionano announces closing of $3 million registered direct offering priced at-the-market under nasdaq rules

San diego, oct. 31, 2024 (globe newswire) -- bionano genomics, inc. (nasdaq: bngo) today announced the closing of its previously announced registered direct offering priced at-the-marker under nasdaq rules for the purchase and sale of an aggregate of 9,881,113 shares of its common stock and series c warrants to purchase up to an aggregate of 9,881,113 shares of common stock and short-term series d warrants to purchase up to an aggregate of 9,881,113 shares of common stock (collectively, the “warrants”) at a combined offering price of $0.3039 per share of common stock and accompanying warrants. the warrants have an exercise price of $0.3039 per share and will be exercisable beginning on the effective date of stockholder approval of the issuance of the shares of common stock upon exercise of the warrants (the “stockholder approval”). the series c warrants expire five years following the date of the stockholder approval and the short-term series d warrants expire eighteen months following the date of stockholder approval.
BNGO Ratings Summary
BNGO Quant Ranking